Bioretec, a pioneer in absorbable orthopedic implants, has appointed Sarah van Hellenberg Hubar-Fisher as Chief Executive Officer (CEO), effective immediately.

Van Hellenberg Hubar-Fisher has served as Bioretec’s interim CEO since May 2025 and as a member of the company’s Board of Directors since 2021. Due to the appointment as permanent CEO, she will step down from her positions as a board member, as Vice Chairperson of the Board, and from her duties on the Board’s audit committee.

She boasts over 23 years of leadership experience in healthcare, medtech, and global public health. In addition to her role at Bioretec, Van Hellenberg Hubar-Fisher is on the Board of Global Surgical Initiatives, a New York-based nonprofit focused on delivering sustainable surgical care to underserved communities.

Her career includes senior leadership roles at Johnson & Johnson, as well as a Venture Partner at Nina Capital (Spain) and Growth Science Ventures (U.S.)

“Sarah brings extensive commercial and management experience in healthcare, including the successful global introduction of new technologies. Her leadership was clearly demonstrated during her time as interim CEO, when she advanced the company’s strategic direction,” said Kustaa Poutiainen, Chairperson of the Board of Directors of Bioretec. “We look forward to Sarah leading Bioretec towards our goal of becoming a global market leader in breakthrough absorbable orthopedic implants.”

“I am excited to lead Bioretec into its next phase of growth as we bring groundbreaking orthopedic technologies to market,” said van Hellenberg Hubar-Fisher. “Our priorities are clear: accelerate the global launch of RemeOs, build on the strong and sustained success of Activa, and ensure both platforms have the resources and processes required for scale. With RemeOs now CE-marked, Activa’s continuing market impact, and a robust innovation pipeline, Bioretec is well positioned to grow its market presence, deliver significant clinical impact, and create long-term value for our shareholders.”